Lund, Sweden, 6 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at Leerink Global Healthcare Conference in Miami, at 13:40 PM EDT on Monday 9 March, 2026. Hansa Biopharma COO and President U.S. Maria Törnsén, and CMO Richard Philipson will […]
Lund, Sweden, 18 February 2026. Hansa Biopharma AB, (“Hansa” or “the Company”), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has been accepted by the U.S. Food and Drug Administration (FDA). FDA’s filing review was completed on day 60 which is meant to verify that the submission is substantially complete […]
Lund, Sweden, 26 January, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its year-end report for January – December 2025 on Wednesday 11 February, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CET / 8:00 AM EST. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, […]
Lund, Sweden, 29 October 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical College of Wisconsin, to provide deeper insights into the medical journey of highly sensitized […]
Hansa Biopharma on 2nd October announced the raise of approximately USD 71 million through directed share issue, with strong support from new shareholders such as Polar Capital LLP, as well as existing shareholders.
